Evidence based answer is needed including all recent trials. -Role of neoadjuvant chemotherapy in breast cancer(all 3 subtypes- TNBC, Her 2 positive, ER+ Her 2 negative) Focus is on benefit of chemotherapy in operable breast cancers. If there is survival benefit, how much is it? I don’t want pcr as surrogate marker. I want actual survival benefit with chemotherapy
Reading File
Finding Sources
Searching PubMed
neoadjuvant chemotherapy triple negative breast cancer overall survival
Searching PubMed
neoadjuvant chemotherapy HER2 positive breast cancer overall survival KATHERINE NOAH
Searching PubMed
neoadjuvant chemotherapy hormone receptor positive HER2 negative breast cancer survival benefit
Reading Article
PMID: 39282906
Reading Article
PMID: 35139274
Searching PubMed
CREATE-X capecitabine triple negative breast cancer residual disease survival
Searching PubMed
KATHERINE T-DM1 HER2 positive residual disease neoadjuvant overall survival
Reading Article
PMID: 39813643
Reading Article
PMID: 28564564
Searching PubMed
NOAH trastuzumab neoadjuvant HER2 breast cancer overall survival
Searching PubMed
neoadjuvant versus adjuvant chemotherapy breast cancer survival equivalence
Reading Article
PMID: 24657003
Reading Article
PMID: 40139460
Searching PubMed
neoadjuvant chemotherapy luminal breast cancer ER positive overall survival benefit
Searching the Web
NACT neoadjuvant chemotherapy operable breast cancer survival benefit ER positive HER2 negative 2024 2025
Reading Web Page
https://ascopost.com/issues/december-10-2024/is-there-a-role…
Reading Article
PMID: 37681577
Reading Article
PMID: 39207778
Searching PubMed
EBCTCG neoadjuvant preoperative chemotherapy breast cancer survival meta-analysis
Searching PubMed
neoadjuvant chemotherapy HER2 positive pertuzumab trastuzumab operable overall survival NeoSphere
Neoadjuvant Chemotherapy in Operable Breast Cancer: Real Survival Benefit by Subtype
Framing the Question Correctly
You are asking the right question. pCR is a surrogate endpoint - it is associated with survival but does not prove that a specific drug causes survival improvement independent of other factors. The only way to know real survival benefit is to look at OS (overall survival) or disease-free/event-free survival from randomized trials. Here is the evidence, subtype by subtype.
1. Triple-Negative Breast Cancer (TNBC)
This is the subtype where neoadjuvant chemotherapy has the strongest real survival data.
Does NACT itself provide a survival advantage over adjuvant chemotherapy?
The EBCTCG meta-analysis (Lancet 2018, PMID 29803425) involving ~4,800 patients from 10 RCTs showed that the timing of chemotherapy (neoadjuvant vs. adjuvant) does not alter overall survival. Patients who achieved pCR had better outcomes, but pCR rate with NACT did not translate into a population-level OS advantage over giving the same chemotherapy adjuvantly. The main benefit of NACT is surgical downstaging. This is the foundational point: NACT and adjuvant chemotherapy are survival-equivalent if the same total chemotherapy is given.
Where the real survival benefit in TNBC comes from: Escalation/De-escalation after NACT
The paradigm shift in TNBC is not NACT vs. no NACT - it is using the pCR/non-pCR response to guide post-neoadjuvant therapy.
CREATE-X trial (Masuda et al., NEJM 2017, PMID 28564564):
- 910 HER2-negative patients with residual disease after standard NACT (anthracycline ± taxane) were randomized to adjuvant capecitabine vs. control
- In the TNBC subgroup specifically:
- 5-year DFS: 69.8% (capecitabine) vs. 56.1% (control) - HR 0.58 (95% CI 0.39-0.87)
- 5-year OS: 78.8% vs. 70.3% - HR 0.52 (95% CI 0.30-0.90)
- This is a ~10% absolute OS benefit at 5 years in non-pCR TNBC patients
- This is real OS benefit, not a surrogate
Adding platinum to NACT in TNBC:
The Cochrane systematic review (Mason et al., 2023, PMID 37681577) analyzed 20 RCTs (1966 participants for DFS/OS endpoints) - high-certainty evidence:
- Neoadjuvant platinum improved DFS: HR 0.63 (95% CI 0.53-0.75)
- Neoadjuvant platinum improved OS: HR 0.69 (95% CI 0.55-0.86)
- This represents a 31% relative reduction in risk of death with carboplatin-containing NACT in early TNBC
KEYNOTE-522: Adding pembrolizumab to NACT in early-stage TNBC
The most important recent trial. Final OS results (Schmid et al., NEJM 2024, PMID 39282906):
- 1174 patients, Stage II-III TNBC, randomized 2:1 to pembrolizumab + chemo (neoadjuvant + adjuvant) vs. chemo alone
- Median follow-up: 75.1 months (>6 years)
- 5-year OS: 86.6% (pembro) vs. 81.7% (placebo), p=0.002
- Absolute OS benefit: ~5% at 5 years
- EFS at 36 months was 84.5% vs. 76.8% (HR 0.63; 95% CI 0.48-0.82)
- Important caveat: pembrolizumab was given both neoadjuvantly and adjuvantly (9 cycles), so this is a combined neoadjuvant + adjuvant immunotherapy benefit, not purely neoadjuvant
- The JAMA Oncology meta-analysis (Villacampa et al., 2024, PMID 39207778) confirmed: in TNBC with pCR after ICI+chemo, 5-year EFS 92.0% vs. 88.0%; in residual disease, 5-year EFS 63.3% vs. 56.1% - the ICI benefit exists in both pCR and non-pCR groups
Summary for TNBC
| Intervention | Trial | Real Survival Benefit |
|---|---|---|
| Platinum in NACT | Cochrane 2023 (20 RCTs) | OS HR 0.69; DFS HR 0.63 (high-certainty) |
| Capecitabine adjuvant (non-pCR) | CREATE-X 2017 | 5yr OS: 78.8% vs. 70.3% (absolute +8.5%) |
| Pembrolizumab + chemo | KEYNOTE-522 2024 | 5yr OS: 86.6% vs. 81.7% (absolute +4.9%) |
Bottom line for TNBC: Chemotherapy is mandatory. The NACT framework unlocks escalation therapy for non-pCR patients (capecitabine, pembrolizumab), which provides a proven OS benefit. TNBC has the most robust actual survival data.
2. HER2-Positive Breast Cancer
Does NACT provide survival benefit vs. adjuvant approach?
Again, the EBCTCG finding applies: NACT and adjuvant chemo are survival-equivalent for the same regimen. The benefit of NACT in HER2+ disease is:
- Enabling breast conservation
- Identifying non-pCR patients who need escalation to T-DM1 (the KATHERINE paradigm)
NOAH Trial - foundational data for trastuzumab-containing NACT
Gianni et al., Lancet Oncology 2014, PMID 24657003 - 235 HER2+ locally advanced/inflammatory BC patients:
- 5-year EFS: 58% (trastuzumab + chemo) vs. 43% (chemo alone) - HR 0.64 (95% CI 0.44-0.93; p=0.016)
- Note: this was locally advanced (some inoperable), not purely operable disease
- OS data in the original NOAH publication (2010) showed 5-year OS 74% vs. 63% with trastuzumab (HR 0.66), but the trial was powered for EFS
KATHERINE trial - the most important HER2+ survival data
This trial defines what to do with non-pCR HER2+ patients after NACT.
- 1486 HER2+ patients with residual invasive disease after neoadjuvant trastuzumab + chemotherapy were randomized to T-DM1 vs. trastuzumab
- 3-year iDFS: 88.3% (T-DM1) vs. 77.0% (trastuzumab) - HR 0.50 (95% CI 0.39-0.64)
KATHERINE final OS analysis (Geyer et al., NEJM January 2025, PMID 39813643) - the landmark 2025 paper:
- Median follow-up: 8.4 years
- iDFS sustained: HR 0.54 (95% CI 0.44-0.66); 7-year iDFS 80.8% (T-DM1) vs. 67.1% (trastuzumab) - absolute difference 13.7 percentage points
- OS: T-DM1 significantly better - HR 0.66 (95% CI 0.51-0.87; p=0.003)
- 7-year OS: 89.1% (T-DM1) vs. 84.4% (trastuzumab) - absolute difference 4.7 percentage points
- Grade 3+ AEs: 26.1% (T-DM1) vs. 15.7% (trastuzumab)
This is now definitive proof that in HER2+ non-pCR patients after NACT, T-DM1 provides a real OS benefit of ~4.7% at 7 years.
What about pertuzumab in NACT for HER2+?
The NeoSphere trial (pertuzumab + trastuzumab + docetaxel vs. trastuzumab + docetaxel) showed improved pCR, but 5-year follow-up (Gianni et al., Lancet Oncology 2016) showed only a trend in PFS (HR 0.69, p=0.094) and no demonstrated OS benefit in operable disease specifically. Pertuzumab in NACT is primarily used to improve pCR (and thereby potentially avoid T-DM1 in the adjuvant setting).
DESTINY-Breast11 (2026)
Harbeck et al., Ann Oncol 2026, PMID 41130363 - neoadjuvant T-DXd alone or followed by taxane/trastuzumab/pertuzumab in high-risk HER2+ EBC. This trial was published in February 2026 and represents the frontier of HER2+ neoadjuvant therapy with ADCs, but OS data are not yet mature.
Summary for HER2+
| Intervention | Trial | Real Survival Benefit |
|---|---|---|
| NACT + trastuzumab vs. chemo alone | NOAH (locally advanced) | 5yr OS ~74% vs. 63%; EFS HR 0.64 |
| T-DM1 adjuvant after non-pCR NACT | KATHERINE 2025 | 7yr OS: 89.1% vs. 84.4%; OS HR 0.66 (p=0.003) |
Bottom line for HER2+: In operable disease, NACT (with trastuzumab ± pertuzumab) is preferred to identify non-pCR patients who derive a proven 4.7% absolute OS benefit at 7 years from adjuvant T-DM1. This is the primary justification for NACT over adjuvant chemotherapy in HER2+ operable BC.
3. ER+/HER2-Negative (Luminal) Breast Cancer
This is where the survival evidence for NACT is most controversial and weakest.
Key conceptual problem
Luminal tumors (especially Luminal A, low Ki-67, low-grade) have low pCR rates (typically 3-10%), meaning most patients do not achieve pCR after NACT. In the EBCTCG meta-analysis and subsequent analyses, patients who do not achieve pCR after NACT do not benefit from having received neoadjuvant vs. adjuvant chemotherapy - in fact, some retrospective analyses suggest non-pCR luminal patients have slightly worse outcomes with NACT compared to adjuvant chemo (possibly selection/timing bias).
Evidence for chemotherapy benefit (not specific to neoadjuvant timing):
The real question in ER+/HER2- is not neoadjuvant vs. adjuvant chemotherapy, but whether chemotherapy at all adds benefit over endocrine therapy. The key trials:
- TAILORx (Sparano et al., NEJM 2018/2019): In node-negative, ER+/HER2-, OncotypeDX Recurrence Score 11-25 patients, chemotherapy + ET vs. ET alone showed no OS or iDFS benefit from chemotherapy in postmenopausal women (absolute difference ~0%). Premenopausal women with RS 16-25 had a small numerical benefit (HR ~0.60 for DFS events at 9 years), but this may reflect endocrine suppression from chemotherapy-induced amenorrhea.
- RxPONDER: Node-positive (1-3 nodes) ER+/HER2-, RS ≤25 patients - no chemo benefit in postmenopausal women; premenopausal women with RS 0-25 had 5-year iDFS improvement (HR 0.54 for distant relapse).
PENELOPE-B (2025) - context for high-risk non-pCR HR+/HER2-
Loibl et al., Ann Oncol 2025, PMID 40139460 - in HR+/HER2- patients with high-risk residual disease after taxane-based NACT:
- Palbociclib + ET vs. placebo + ET: No OS benefit (HR 0.87, 95% CI 0.67-1.14; p=0.31)
- 6-year OS: 82.4% vs. 80.3% - no significant difference
- This tells us that even after selecting the highest-risk non-pCR HR+/HER2- patients post-NACT, CDK4/6 inhibitor escalation did not improve survival (though monarchE abemaciclib does show OS benefit in high-risk HR+ overall)
Can NACT identify patients who will benefit from escalation?
Unlike TNBC (capecitabine) and HER2+ (T-DM1), there is currently no approved escalation therapy for non-pCR HR+/HER2- patients specifically informed by NACT response that shows an OS benefit. PENELOPE-B failed. The NATALEE trial (ribociclib) and monarchE (abemaciclib) showed OS/DFS benefits in high-risk HR+ patients regardless of neoadjuvant vs. adjuvant chemo history.
SEER database / retrospective evidence
A 2024 retrospective SEER analysis of T2N1M0 HR+/HER2- patients found that NACT was actually associated with worse survival compared to adjuvant chemotherapy in non-pCR patients, and that this subtype has the least to gain from the neoadjuvant approach outside of surgical downstaging goals.
Summary for ER+/HER2-
| Context | Evidence | Survival Benefit from NACT? |
|---|---|---|
| Low/intermediate RS, node-negative | TAILORx | Chemotherapy benefit near-zero in postmenopausal; marginal in premenopausal |
| Node-positive, RS ≤25 | RxPONDER | No chemo benefit postmenopausal; benefit in premenopausal may be hormonal |
| High-risk residual disease after NACT | PENELOPE-B 2025 | No OS benefit from escalation with palbociclib post-NACT |
| Neoadjuvant vs. adjuvant timing | EBCTCG | Survival equivalent; NACT confers no OS advantage over adjuvant timing |
Bottom line for ER+/HER2-: NACT has no proven OS advantage over adjuvant chemotherapy in this subtype. The pCR rate is low, the non-pCR state does not have proven escalation options (unlike TNBC/HER2+), and retrospective data suggest possible harm in non-pCR patients. NACT in ER+/HER2- should only be used when surgical downstaging is specifically needed (large tumor, inflammatory presentation, lymph node downstaging for axillary conservation). For most operable ER+/HER2- tumors, adjuvant endocrine therapy ± chemotherapy (guided by genomic testing) remains the standard, with adjuvant CDK4/6 inhibitors (abemaciclib, ribociclib) providing documented OS/iDFS benefits.
Overall Synthesis: Is NACT Better Than Adjuvant Chemotherapy for Survival?
The fundamental EBCTCG finding still stands: neoadjuvant and adjuvant chemotherapy produce equivalent survival outcomes when the same total chemotherapy is administered. NACT does not "cure more cancer" by being given earlier.
The reason NACT is preferred in TNBC and HER2+ is entirely strategic - using pathological response as a biomarker to escalate post-neoadjuvant therapy (T-DM1 in HER2+ non-pCR; capecitabine ± pembrolizumab in TNBC non-pCR). This paradigm has now produced real, proven OS benefits:
| Subtype | Trial | OS Benefit (Absolute) |
|---|---|---|
| TNBC - platinum NACT | Cochrane meta-analysis 2023 | OS HR 0.69 (high-certainty) |
| TNBC - capecitabine after non-pCR | CREATE-X 2017 | ~+8.5% at 5 years |
| TNBC - pembro + chemo | KEYNOTE-522 2024 | +4.9% at 5 years (p=0.002) |
| HER2+ - T-DM1 in non-pCR | KATHERINE 2025 | +4.7% at 7 years (p=0.003) |
| ER+/HER2- | No trial | No proven OS benefit from NACT |
For ER+/HER2- tumors in operable settings, the question is not NACT vs. adjuvant chemo - it is whether chemotherapy is needed at all, guided by genomic assays. The survival benefit of chemotherapy in this subtype is confined to specific high-risk groups and is largely seen in premenopausal women.
This is a shared conversation. Sign in to Orris to start your own chat.